Capricor Therapeutics CAPR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's cash & equivalents?
- Capricor Therapeutics (CAPR) reported cash & equivalents of $105.42M in Q1 2026.
- How has Capricor Therapeutics's cash & equivalents changed year-over-year?
- Capricor Therapeutics's cash & equivalents increased by 266.1% year-over-year, from $28.79M to $105.42M.
- What is the long-term trend for Capricor Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Capricor Therapeutics's cash & equivalents has grown at a 54.5% compound annual growth rate (CAGR), from $32.67M to $287.85M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.